Gilead Sciences (GILD) Stock Forecast & Price Target

Gilead Sciences is attractive because its core HIV franchise remains highly resilient, with Biktarvy, Descovy, and Yeztugo all showing strong demand, 95% U.S. coverage, and guidance for FY26 revenue of $30.0-30.4B after a top-line beat. The company is also extending its leadership in PrEP through longer-acting options and an FDA-accepted oral Yeztugo filing for Feb 2, 2027, which could deepen its competitive moat and support durable growth into the 2030s. Beyond HIV, Gilead is building a more diversified growth profile through oncology assets such as Yescarta, Tecartus, Trodelvy, and anito-cel, while its liver and HCV businesses continue to generate meaningful cash flows.

Gilead Sciences is facing a negative fundamental setup because its core HIV franchise is under pressure from weak PrEP persistence, slower-than-expected Yeztugo uptake, and competition from Biktarvy and generic HIV entrants, leaving shares down 7.5% MTD versus peers flat. The company also faces execution risk outside HIV, as investors have yet to see clear acceleration in scripts, meaningful buy-and-bill adoption, or convincing growth from TUB-040 and the α4β7 program, while HCV remains exposed to competition and pricing pressure. Oncology adds uncertainty rather than clarity, with cautious views on anito-cel, slower Yescarta uptake, and disappointing Trodelvy data in EVOKE-3, alongside risks from federal funding cuts and broader M&A concerns that could weigh on estimates.